Pasithea Therapeutics Corp. Annual report pursuant to Section 13 and 15(d)

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2023

Purchase consideration consisted of the following:

Equity consideration	$	3,293,479
Warrants issued as consideration		680,000
Total purchase consideration	$	3,973,479

The fair values of the acquired assets and liabilities as of the acquisition date were:

Cash	$	77,060
Prepaid assets		49,380
Fixed assets		19,551
In-process research and development		2,900,000
Accounts payable & accrued expenses		(335,423	)
Net assets acquired, excluding Goodwill		2,710,568
Goodwill		1,262,911

The cost of the asset acquisition included the purchase consideration as well as transaction expenses, as follows:

135,000 shares of Pasithea common stock	$	3,402,000
Warrants to acquire 50,000 shares of common stock at exercise price of $37.60		522,358
Cash		1,000,000
Non-refundable payment for AlloMek transaction expenses		50,000
Pasithea transaction expenses		697,121
Total cost of asset acquisition	$	5,671,479